Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders

Nature Reviews Drug Discovery

Volumn 9, Issue 12, 2010, Pages 971-988

  Rupprecht, Rainer ^a,b   Papadopoulos, Vassilios ^c   Rammes, Gerhard ^b,d   Baghai, Thomas C ^a   Fan, Jinjiang ^c   Akula, Nagaraju ^e   Groyer, Ghislaine ^f   Adams, David ^g   Schumacher, Michael ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f Universite Paris Sud   (France)

^g BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4' CHLORODIAZEPAM; ADENINE NUCLEOTIDE TRANSLOCASE; ARYLINDOL ACETAMIDE; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZOTHIAZEPINE; BENZOXAZEPINE; CHOLESTEROL; DAA 1106; DIAZEPAM; DPA 713; EMAPUNIL; ETIFOXINE; FGIN 1 27; FLUNITRAZEPAM; IMIDAZOPYRIDINE ACETAMIDE; IMIDAZOPYRIDINE DERIVATIVE; IND 18; MEMBRANE PROTEIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; OCTADECANEUROPEPTIDE; OLESOXIME; PHENOXYPHENYL ACETAMIDE; PHENYLINDOLYLGLYOXYLAMIDE; PORPHYRIN; PROTOPORPHYRIN; PYRAZOLO PYRIMIDINE ACETAMIDE; PYRIDAZINOINDOLE ACETAMIDE; QUINOLINE CARBOXAMIDE; SSR 180575; THIA 66; TRANSLOCATOR PROTEIN; TRANSLOCATOR PROTEIN 2; TRO 19622; UNCLASSIFIED DRUG; UNINDEXED DRUG; VC 198M; VINPOCETINE; VOLTAGE DEPENDENT ANION CHANNEL;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; BINDING AFFINITY; BINDING SITE; BRAIN DAMAGE; BRAIN TUMOR; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DIABETIC NEUROPATHY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG STRUCTURE; GANGLION; GENETIC POLYMORPHISM; HUMAN; MENTAL DISEASE; MICROGLIA; MITOCHONDRIAL MEMBRANE; NERVE INJURY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; OLFACTORY BULB; PAIN; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SCIATIC NERVE INJURY; SEQUENCE HOMOLOGY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; RECEPTORS, GABA;

EID: 78649687576     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3295     Document Type: Review

References (207)

1. Papadopoulos, V. et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27, 402-409 (2006).
2. Papadopoulos, V., Liu, J. & Culty, M. Is there a mitochondrial signaling complex facilitating cholesterol import? Mol. Cell Endocrinol. 266, 59-64 (2007).
3. Jorda, E. G. et al. Evidence in favour of a role for peripheral-type benzodiazepine receptor ligands in amplification of neuronal apoptosis. Apoptosis 10, 91-104 (2005).
4. Jayakumar, A. R., Panickar, K. S. & Norenberg, M. D. Effects on free radical generation by ligands of the peripheral benzodiazepine receptor in cultured neural cells. J. Neurochem. 83, 1226-1234 (2002).
5. Delavoie, F. et al. In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry 42, 4506-4519 (2003).
6. Lacapere, J. J. & Papadopoulos, V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids 68, 569-585 (2003).
7. Chen, M. K. & Guilarte, T. R. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol. Ther. 11 8, 1-17 (2008).
8. 11 C]PK11195 challengers. Eur. J. Nucl. Med. Mol. Imaging 35, 2304-2319 (2008).
9. 11 C-AC-5216. J. Nucl. Med. 50, 1095-1101 (2009).
10. Girard, C. et al. Etifoxine improves peripheral nerve regeneration and functional recovery. Proc. Natl Acad. Sci. USA 105, 20505-20510 (2008).
11. Da Settimo, F. et al. Anxiolytic-like effects of N, N-dialkyl-2- phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J. Med. Chem. 51, 5798-5806 (2008).
12. Rupprecht, R. et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490-493 (2009).
13. Anholt, R. R., Pedersen, P. L., De Souza, E. B. & Snyder, S. H. The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J. Biol. Chem. 261, 576-583 (1986).
14. Joseph-Liauzun, E., Delmas, P., Shire, D. & Ferrara, P. Topological analysis of the peripheral benzodiazepine receptor in yeast mitochondrial membranes supports a five-transmembrane structure. J. Biol. Chem. 273, 2146-2152 (1998).
15. McEnery, M. W., Snowman, A. M., Trifiletti, R. R. & Snyder, S. H. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc. Natl Acad. Sci. USA 89, 3170-3174 (1992).
16. Garnier, M. et al. In vitro reconstitution of a functional peripheral-type benzodiazepine receptor from mouse Leydig tumor cells. Mol. Pharmacol. 45, 201-211 (1994).
17. Veenman, L., Shandalov, Y. & Gavish, M. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J. Bioenerg. Biomembr. 40, 199-205 (2008).
18. Culty, M. et al. In vitro studies on the role of the peripheral-type benzodiazepine receptor in steroidogenesis. J. Steroid. Biochem. Mol. Biol. 69, 123-130 (1999). (Pubitemid 29305530)
19. Liu, J., Rone, M. B. & Papadopoulos, V. Protein- protein interactions mediate mitochondrial cholesterol transport and steroid biosynthesis. J. Biol. Chem. 281, 38879-38893 (2006).
20. Rone, M. B., Fan, J. & Papadopoulos, V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim. Biophys. Acta 1791, 646-658 (2009).
21. Fan, J., Rone, M. B. & Papadopoulos, V. Translocator protein 2 is involved in cholesterol redistribution during erythropoiesis. J. Biol. Chem. 284, 30484-30497 (2009).
22. Papadopoulos, V. et al. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids 62, 21-28 (1997).
23. Casellas, P., Galiegue, S. & Basile, A. S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem. Int. 40, 475-486 (2002).
24. Gavish, M. et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 51, 29-650 (1999).
25. Kuhlmann, A. C. & Guilarte, T. R. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J. Neurochem. 74, 1694-1704 (2000).
26. Maeda, J. et al. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res. 1157, 100-111 (2007).
27. Anholt, R. R., Murphy, K. M., Mack, G. E. & Snyder, S. H. Peripheral-type benzodiazepine receptors in the central nervous system: localization to olfactory nerves. J. Neurosci. 4, 593-603 (1984).
28. Bolger, G. T . et al. Differential regulation of 'central' and 'peripheral' benzodiazepine binding sites in the rat olfactory bulb. Eur. J. Pharmacol. 105, 143-148 (1984).
29. Decaudin, D. et al. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 62, 1388-1393 (2002).
30. Karchewski, L. A., Bloechlinger, S. & Woolf, C. J. Axonal injury-dependent induction of the peripheral benzodiazepine receptor in small-diameter adult rat primary sensory neurons. Eur. J. Neurosci. 20, 671-683 (2004).
31. Hirsch, J. D., Beyer, C. F., Malkowitz, L., Beer, B. & Blume, A. J. Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory control. Mol. Pharmacol. 35, 157-163 (1989).
32. Corsi, L., Geminiani, E. & Baraldi, M. Peripheral benzodiazepine receptor (PBR) new insight in cell proliferation and cell differentiation review. Curr. Clin. Pharmacol. 3, 38-45 (2008).
33. Veenman, L., Papadopoulos, V. & Gavish, M. Channellike functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr. Pharm. Des. 13, 2385-2405 (2007).
34. Garnier, M., Boujrad, N., Ogwuegbu, S. O., Hudson, J. R., Jr & Papadopoulos, V. The polypeptide diazepam-binding inhibitor and a higher affinity mitochondrial peripheral-type benzodiazepine receptor sustain constitutive steroidogenesis in the R2C Leydig tumor cell line. J. Biol. Chem. 269, 22105-22112 (1994).
35. Kelly-Hershkovitz, E. et al. Effects of peripheral-type benzodiazepine receptor antisense knockout on MA-10 Leydig cell proliferation and steroidogenesis. J. Biol. Chem. 273, 5478-5483 (1998).
36. Levin, E. et al. The peripheral-type benzodiazepine receptor and tumorigenicity: isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line. Biochemistry 44, 9924-9935 (2005).
37. Hauet, T. et al. Peripheral-type benzodiazepine receptor-mediated action of steroidogenic acute regulatory protein on cholesterol entry into Leydig cell mitochondria. Mol. Endocrinol. 19, 540-554 (2005).
38. Kletsas, D., Li, W., Han, Z. & Papadopoulos, V. Peripheral-type benzodiazepine receptor (PBR) and PBR drug ligands in fibroblast and fibrosarcoma cell proliferation: role of ERK, c-Jun and ligand-activated PBR-independent pathways. Biochem. Pharmacol. 67, 1927-1932 (2004).
39. Li, W., Hardwick, M. J., Rosenthal, D., Culty, M. & Papadopoulos, V. Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation. Biochem. Pharmacol. 73, 491-503 (2007).
40. (2) induces apoptosis via the 18 kDa translocator protein in U118MG human glioblastoma cells. Biochemistry 48, 4652-4661 (2009).
41. Hales, D. B. et al. Mitochondrial function in Leydig cell steroidogenesis. Ann. NY Acad. Sci. 1061, 120-134 (2005).
42. Bernassau, J. M., Reversat, J. L., Ferrara, P., Caput, D. & Lefur, G. A 3D model of the peripheral benzodia zepine receptor and its implication in intra mitochon drial cholesterol transport. J. Mol. Graph. 11, 236-244 (1993). (Pubitemid 2021639)
43. Li, H. & Papadopoulos, V. Peripheral-type benzo-diazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/ interaction amino acid sequence and consensus pattern. Endocrinology 139, 4991-4997 (1998).
44. Li, H., Yao, Z., Degenhardt, B., Teper, G. & Papadopoulos, V. Cholesterol binding at the cholesterol recognition/ interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc. Natl Acad. Sci. USA 98, 1267-1272 (2001).
45. Jamin, N. et al. Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. Mol. Endocrinol. 19, 588-594 (2005).
46. Lacapere, J. J. et al. Structural and functional study of reconstituted peripheral benzodiazepine receptor. Biochem. Biophys. Res. Commun. 284, 536-541 (2001).
47. Murail, S. et al. Secondary and tertiary structures of the transmembrane domains of the translocator protein TSPO determined by NMR. Stabilization of the TSPO tertiary fold upon ligand binding. Biochim. Biophys. Acta 1778, 1375-1381 (2008).
48. Korkhov, V. M., Sachse, C., Short, J. M. & Tate, C. G. Three-dimensional structure of TSPO by electron cryomicroscopy of helical crystals. Structure 18, 677-687 (2010).
49. 3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J. Cereb. Blood Flow Metab. 30, 1608-1618 (2010).
50. Mills, C. D., Bitler, J. L. & Woolf, C. J. Role of the peripheral benzodiazepine receptor in sensory neuron regeneration. Mol. Cell. Neurosci. 30, 228-237 (2005).
51. Lacor, P. et al. Regulation of the expression of peripheral benzodiazepine receptors and their endogenous ligands during rat sciatic nerve degeneration and regeneration: a role for PBR in neurosteroidogenesis. Brain Res. 815, 70-80 (1999).
52. Costigan, M. et al. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci. 3, 16 (2002).
53. Wang, H. et al. Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases. Neuroscience 11 4, 529-546 (2002).
54. Xiao, H. S. et al. Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc. Natl Acad. Sci. USA 99, 8360-8365 (2002).
55. Banati, R. B. Visualising microglial activation in vivo. Glia 40, 206-217 (2002).
56. Maeda, J. et al. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res. 1157, 100-111 (2007).
57. Chen, M. K., Baidoo, K., Verina, T. & Guilarte, T. R. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain 127, 1379-1392 (2004).
58. 11 C](R)-PK11195 PET study. Neuroimage 24, 591-595 (2005).
59. Moustafa, R. R. & Baron, J. C. Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br. J. Pharmacol. 153, S44-S54 (2008).
60. Venneti, S. et al. The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: implications for PET imaging. Exp. Neurol. 207, 118-127 (2007).
61. Papadopoulos, V. & Lecanu, L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp. Neurol. 217, 53-57 (2009).
62. Cosenza-Nashat, M. et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol. Appl. Neurobiol. 35, 306-328 (2009).
63. 11 C] PIB-PET study. Neurobiol. Dis. 32, 412-419 (2008).
64. 11 C] DAA1106. Biol. Psychiatry 64, 835-841 (2008).
65. Papadopoulos, V., Lecanu, L., Brown, R. C., Han, Z. & Yao, Z. X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 138, 749-756 (2006).
66. Cagnin, A., Rossor, M., Sampson, E. L., Mackinnon, T. & Banati, R. B. In vivo detection of microglial activation in frontotemporal dementia. Ann. Neurol. 56, 894-897 (2004).
67. Vowinckel, E. et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neurosci. Res. 50, 345-353 (1997).
68. Versijpt, J. et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult. Scler. 11, 127-134 (2005).
69. Pavese, N. et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66, 1638-1643 (2006). (Pubitemid 43964614)
70. 11 C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 15, 601-609 (2004).
71. Ouchi, Y. et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175 (2005).
72. 11 C](R.)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21, 404-412 (2006). (Pubitemid 43099863)
73. Ji, B. et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J. Neurosci. 28, 12255-12267 (2008).
74. Agnello, D. et al. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J. Neuroimmunol. 109, 105-111 (2000).
75. Vlodavsky, E. & Soustiel, J. F. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J. Neurooncol. 81, 1-7 (2007).
76. Bai, M., Rone, M. B., Papadopoulos, V. & Bornhop, D. J. A novel functional translocator protein ligand for cancer imaging. Bioconjug. Chem. 18, 2018-2023 (2007).
77. 18F]PBR06 for PET imaging of glioma. J. Nucl. Med. 51, 279 (2010).
78. Yamasaki, T. et al. Imaging of peripheral-type benzodiazepine receptor in tumor: in vitro binding and in vivo biodistribution of N-benzyl-N-[(11)C] methyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro-19H-purin-9-yl)acetamide. Nucl. Med. Biol. 36, 801-809 (2009).
79. Romeo, E. et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry 155, 910-913 (1998).
80. Rupprecht, R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28, 139-168 (2003).
81. Ströhle, A. et al. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch. Gen. Psychiatry 60, 161-168 (2003).
82. Nudmamud, S. et al. Stress, anxiety and peripheral benzodiazepine receptor mRNA levels in human lymphocytes. Life Sci. 67, 2221-2231 (2000).
83. Rocca, P. et al. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Biol. Psychiatry 43, 767-773 (1998).
84. Chelli, B. et al. Platelet 18 kDa translocator protein density is reduced in depressed patients with adult separation anxiety. Eur. Neuropsychopharmacol. 18, 249-254 (2008).
85. Gavish, M. et al. Altered platelet peripheral-type benzodiazepine receptor in posttraumatic stress disorder. Neuropsychopharmacology 14, 181-186 (1996).
86. Johnson, M. R. et al. Abnormal peripheral benzodiazepine receptor density associated with generalized social phobia. Biol. Psychiatry 43, 306-309 (1998).
87. Nakamura, K., Fukunishi, I., Nakamoto, Y., Iwahashi, K. & Yoshii, M. Peripheral-type benzodiazepine receptors on platelets are correlated with the degrees of anxiety in normal human subjects. Psychopharmacology 162, 301-303 (2002).
88. Pini, S. et al. Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. Psychopharmacology 181, 407-411 (2005).
89. Ritsner, M. et al. Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients. J. Psychiatr. Res. 37, 549-556 (2003).
90. Soreni, N. et al. Decreased platelet peripheral-type benzodiazepine receptors in adolscent inpatients with repeated suicice attempts. Biol. Psychiatry 46, 484-488 (1999).
91. Weizman, A., Burgin, R., Harel, Y., Karp, L. & Gavish, M. Platelet peripheral-type benzodiazepine receptor in major depression. J. Affect. Disord. 33, 257-261 (1995).
92. Abelli, M. et al. Reductions in platelet 18-kDa translocator protein density are associated with adult separation anxiety in patients with bipolar disorder. Neuropsychobiology 62, 98-103 (2010).
93. Costa, B. et al. Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. Psychiatr. Genet. 19, 110-111 (2009).
94. Costa, B. et al. The spontaneous Ala147Thr amino acid substitution within the translocator protein influences pregnenolone production in lymphomonocytes of healthy individuals. Endocrinology 150, 5438-5445 (2009).
95. Nakamura, K. et al. Evidence that variation in the peripheral benzodiazepine receptor (PBR) gene influences susceptibility to panic disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 222-226 (2006).
96. 11 C]DAA1106. Int. J. Neuropsychopharmacol. 13, 943-950 (2010).
97. Verma, A., Nye, J. S. & Snyder, S. H. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc. Natl Acad. Sci. USA 84, 2256-2260 (1987).
98. Costa, E. & Guidotti, A. Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci. 49, 325-344 (1991).
99. Farges, R. et al. Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864 Mol. Pharmacol. 46, 1160-1167 (1994).
100. Anzini, M. et al. Mapping and fitting the peripheral benzodiazepine receptor binding site by carboxamide derivatives. Comparison of different approaches to quantitative ligand-receptor interaction modeling. J. Med. Chem. 44, 1134-1150 (2001).
101. Joseph-Liauzun, E., Farges, R., Delmas, P., Ferrara, P. & Loison, G. The Mr 18, 000 subunit of the peripheral-type benzodiazepine receptor exhibits both benzodiazepine and isoquinoline carboxamide binding sites in the absence of the voltage-dependent anion channel or of the adenine nucleotide carrier. J. Biol. Chem. 272, 28102-28106 (1997).
102. Mocchetti, I. & Santi, M. R. Diazepam binding inhibitor peptide: cloning and gene expression. Neuropharmacology 30, 1365-1371 (1991).
103. do Rego, J. C. et al. Pharmacological characterization of the receptor mediating the anorexigenic action of the octadecaneuropeptide: evidence for an endozepinergic tone regulating food intake. Neuropsychopharmacology 32, 1641-1648 (2007).
104. Papadopoulos, V., Berkovich, A., Krueger, K. E., Costa, E. & Guidotti, A. Diazepam binding inhibitor and its processing products stimulate mitochondrial steroid biosynthesis via an interaction with mitochondrial benzodiazepine receptors. Endocrinology 129, 1481-1488 (1991).
105. Faergeman, N. J. et al. Acyl-CoA binding proteins; structural and functional conservation over 2000 MYA. Mol. Cell. Biochem. 299, 55-65 (2007).
106. Fan, J., Liu, J., Culty, M. & Papadopoulos, V. Acyl-coenzyme A binding domain containing 3 (ACBD3; PAP7; GCP60): an emerging signaling molecule. Prog. Lipid. Res. 49, 218-234 (2010).
107. Li, H. et al. Identification, localization, and function in steroidogenesis of PAP7: a peripheral-type benzodiazepine receptor- and PKA (RIalpha)-associated protein. Mol. Endocrinol. 15, 2211-2228 (2001).
108. Skowronski, R., Beaumont, K. & Fanestil, D. D. Modification of the peripheral-type benzodiazepine receptor by arachidonate, diethylpyrocarbonate and thiol reagents. Eur. J. Pharmacol. 143, 305-314 (1987).
109. Artemenko, I. P. & Jefcoate, C. R. Multiple contributions from long-chain fatty acid metabolism in Y-1 and MA-10 cells. Endocr. Res. 30, 637 (2004).
110. Tokay, T. et al. Beta-amyloid peptide stimulates endozepine release in cultured rat astrocytes through activation of N-formyl peptide receptors. Glia 56, 1380-1389 (2008).
111. Ferrarese, C. et al. Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia. Neurology 40, 632-635 (1990).
112. Verleye, M. et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol. Biochem. Behav. 82, 712-720 (2005).
113. A receptors are mediated by the beta subunit. Neuropharmacology 45, 293-303 (2003).
114. Schlichter, R., Rybalchenko, V., Poisbeau, P., Verleye, M. & Gillardin, J. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 39, 1523-1535 (2000).
115. Nguyen, N. et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Human Psychopharmacology 21, 139-149 (2006).
116. Langer, S. Z., Arbilla, S., Benavides, J. & Scatton, B. Zolpidem and alpidem: two imidazopyridines with selectivity for omega 1- and omega 3-receptor subtypes. Adv. Biochem. Psychopharmacol. 46, 61-72 (1990).
117. Ausset, P. et al. Subfulminant hepatitis caused by alpidem and treated by liver transplantation. Gastroenterol. Clin. Biol. 19, 222-223 (1995).
118. Barki, J. et al. Fatal subfulminant hepatitis during treatment with alpidem (Ananxyl). Gastroenterol. Clin. Biol. 17, 872-874 (1993).
119. Baty, V. et al. Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal. Gastroenterol. Clin. Biol. 18, 1129-1131 (1994).
120. Ferzaz, B. et al. SSR180575 (7-chloro-N, N, 5-trimethyl-4-oxo-3-phenyl-3, 5-dihydro-4H-pyridazino[4, 5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J. Pharmacol. Exp. Ther. 301, 1067-1078 (2002).
121. Bordet, T. et al. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J. Pharmacol. Exp. Ther. 326, 623-632 (2008).
122. Giatti, S. et al. Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience 164, 520-529 (2009).
123. Aouad, M., Charlet, A., Rodeau, J. L. & Poisbeau, P. Reduction and prevention of vincristine-induced neuropathic pain symptoms by the non-benzodiazepine anxiolytic etifoxine are mediated by 3alpha-reduced neurosteroids. Pain 147, 54-59 (2009).
124. Bordet, T. et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 322, 709-720 (2007).
125. Veiga, S., Azcoitia, I. & Garcia-Segura, L. M. Ro5- 4864, a peripheral benzodiazepine receptor ligand, reduces reactive gliosis and protects hippocampal hilar neurons from kainic acid excitotoxicity. J. Neurosci. Res. 80, 129-137 (2005).
126. Soustiel, J. F . et al. Neuroprotective effect of Ro5-4864 following brain injury. Exp. Neurol. 214, 201-208 (2008).
127. James, M. L., Selleri, S. & Kassiou, M. Development of ligands for the peripheral benzodiazepine receptor. Curr. Med. Chem. 13, 1991-2001 (2006).
128. AR and hypothermic effects. Neurochem. Int. 55, 164-173 (2009).
129. Kunduzova, O. R. et al. Involvement of peripheral benzodiazepine receptor in the oxidative stress, death-signaling pathways, and renal injury induced by ischemia-reperfusion. J. Am. Soc. Nephrol. 15, 2152-2160 (2004).
130. Veenman, L. & Gavish, M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol. Ther. 11 0, 503-524 (2006).
131. Totis, M. et al. Induction of liver microsomal cytochrome P-450 isozymes by 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide. Xenobiotica 19, 857-866 (1989).
132. Chen, Z. L., Yu, W. M. & Strickland, S. Peripheral regeneration. Annu. Rev. Neurosci. 30, 209-233 (2007).
133. Torres, S. R. et al. Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation. Eur. J. Pharmacol. 408, 199-211 (2000).
134. Benavides, J., Dubois, A. & Scatton, B. Peripheral type benzodiazepine binding sites as a tool for the detection and quantification of CNS injury. Curr. Protoc. Neurosci. 1 May 2001 (doi:10.1002/0471142301. ns0716s09).
135. Hanisch, U. K. & Kettenmann, H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nature Neurosci. 10, 1387-1394 (2007).
136. Ekdahl, C. T., Kokaia, Z. & Lindvall, O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 158, 1021-1029 (2009).
137. Franklin, R. J. Why does remyelination fail in multiple sclerosis? Nature Rev. Neurosci. 3, 705-714 (2002).
138. Neumann, H., Kotter, M. R. & Franklin, R. J. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132, 288-295 (2009).
139. Block, M. L., Zecca, L. & Hong, J. S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Rev. Neurosci. 8, 57-69 (2007).
140. Ryu, J. K., Choi, H. B. & McLarnon, J. G. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol. Dis. 20, 550-561 (2005).
141. Veiga, S., Carrero, P., Pernia, O., Azcoitia, I. & Garcia-Segura, L. M. Translocator protein 18 kDa is involved in the regulation of reactive gliosis. Glia 55, 1426-1436 (2007).
142. Rechichi, M. et al. TSPO over-expression increases motility, transmigration and proliferation properties of C6 rat glioma cells. Biochim. Biophys. Acta 1782, 118-125 (2008).
143. Gonzalez-Polo, R. A. et al. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene 24, 7503-7513 (2005).
144. Hans, G. et al. Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression. Biochem. Pharmacol. 69, 819-830 (2005).
145. Kugler, W. et al. Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphospho-homocholine. Cell. Oncol. 30, 435-450 (2008).
146. Strohmeier, R., Roller, M., Sanger, N., Knecht, R. & Kuhl, H. Modulation of tamoxifen-induced apoptosis by peripheral benzodiazepine receptor ligands in breast cancer cells. Biochem. Pharmacol. 64, 99-107 (2002).
147. Kita, A. et al. Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br. J. Pharmacol. 142, 1059-1072 (2004).
148. Okuyama, S. et al. Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA 1091 and DAA 1106. Life Sci. 64, 1455-1464 (1999).
149. Serra, M. et al. 2-Phenyl-imidazo[1,2-a]pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats. Br. J. Pharmacol. 127, 177-187 (1999).
150. A receptor activity. Psychoneuroendocrinology 19 Aug 2010 (doi:10.1016/j.psyneuen.2010.07.021).
151. Kita, A., Kinoshita, T., Kohayakawa, H., Furukawa, K. & Akaike, A. Lack of tolerance to anxiolysis and withdrawal symptoms in mice repeatedly treated with AC-5216, a selective TSPO ligand. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1040-1045 (2009).
152. Costa, B. et al. Peripheral benzodiazepine receptor: characterization in human T-lymphoma Jurkat cells. Mol. Pharmacol. 69, 37-44 (2006).
153. Chen, M. K. & Guilarte, T. R. Imaging the peripheral benzodiazepine receptor response in central nervous system demyelination and remyelination. Toxicol. Sci. 91, 532-539 (2006).
154. 11 C] PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. J. Cereb. Blood Flow Metab. 27, 1975-1986 (2007).
155. Le Goascogne, C. et al. Neurosteroid progesterone is up-regulated in the brain of jimpy and shiverer mice. Glia 29, 14-24 (2000).
156. 2+-induced permeability transition pore opening in rat brain mitochondria. Cell. Calcium 42, 27-39 (2007).
157. Parker, M. A., Bazan, H. E., Marcheselli, V., Rodriguez de Turco, E. B. & Bazan, N. G., Platelet-activating factor induces permeability transition and cytochrome c release in isolated brain mitochondria. J. Neurosci. Res. 69, 39-50 (2002).
158. Obame, F. N., Zini, R., Souktani, R., Berdeaux, A. & Morin, D. Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. J. Pharmacol. Exp. Ther. 323, 336-345 (2007).
159. Besman, M. J. et al. Identification of des-(Gly-Ile)-endozepine as an effector of corticotropin-dependent adrenal steroidogenesis: stimulation of cholesterol delivery is mediated by the peripheral benzodiazepine receptor. Proc. Natl Acad. Sci. USA 86, 4897-4901 (1989).
160. Rupprecht, R. & Holsboer, F. Neuroactive steroids: mechanisms of action and neuropsycho-pharmacological perspectives. Trends Neurosci. 22, 410-416 (1999).
161. Stoffel-Wagner, B., Neurosteroid metabolism in the human brain. Eur. J. Endocrinol. 145, 669-679 (2001).
162. Papadopoulos, V., Guarneri, P., Kreuger, K. E., Guidotti, A. & Costa, E. Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor. Proc. Natl Acad. Sci. USA 89, 5113-5117 (1992).
163. Bitran, D., Foley, M., Audette, D., Leslie, N. & Frye, C. A. Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rat. Psychopharmacology 151, 64-71 (2000).
164. Korneyev, A. et al. Stimulation of brain pregnenolone synthesis by mitochondrial diazepam binding inhibitor receptor ligands in vivo. J. Neurochem. 61, 1515-1524 (1993).
165. Romeo, E. et al., Stimulation of brain steroidogenesis by 2-aryl-indole-3-acetamide derivatives acting at the mitochondrial diazepam-binding inhibitor receptor complex. J. Pharmacol. Exp. Ther. 267,
166. Poisbeau, P. et al. Inflammatory pain upregulates spinal inhibition via endogenous neurosteroid production. J. Neurosci. 25, 11768-11776 (2005).
167. A receptor-mediated miniature IPSCs in the dorsal horn of the rat spinal cord are determined by mitochondrial transport of cholesterol. J. Neurosci. 28, 3427-3437 (2008).
168. Zheng, P. Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance. Prog. Neurobiol. 89, 134-152 (2009).
169. A receptors. Psychoneuroendocrinology 34, S48-S58 (2009).
170. Melcangi, R. C., Celotti, F. & Martini, L. Progesterone 5-alpha-reduction in neuronal and in different types of glial cell cultures: type 1 and 2 astrocytes and oligodendrocytes. Brain Res. 639, 202-206 (1994).
171. Melcangi, R. C. et al. The 5alpha-reductase in the central nervous system: expression and modes of control. J. Steroid. Biochem. Mol. Biol. 65, 295-299 (1998).
172. Tsuruo, Y., Topography and function of androgen-metabolizing enzymes in the central nervous system. Anat. Sci. Int. 80, 1-11 (2005).
173. Agis-Balboa, R. C. et al. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc. Natl Acad. Sci. USA 103, 14602-14607 (2006).
174. Venneti, S., Lopresti, B. J. & Wiley, C. A. The peripheral benzodiazepine receptor (translocator protein 18kDa) in microglia: from pathology to imaging. Prog. Neurobiol. 80, 308-322 (2006).
175. A receptors of thalamocortical neurons: a molecular target for hypnotics. J. Neurosci. 25, 11513-11520 (2005).
176. A receptors. J. Physiol. 497, 753-759 (1996).
177. A receptor alpha 4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol. Proc. Natl Acad. Sci. 103, 15230-15235 (2006).
178. Fritschy, J. M. & Brunig, I. Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol. Ther. 98, 299-323 (2003).
179. A receptor subunits are necessary for tonic inhibition in the hippocampus? J. Neurosci. 28, 1421-1426 (2008).
180. A beta subunit isoforms in synaptic and extrasynaptic receptor populations of mouse dentate gyrus granule cells. J. Physiol. 586, 989-1004 (2008).
181. A receptors on rat hippocampal pyramidal neurons. J. Physiol. 577, 841-856 (2006).
182. A receptors in mouse thalamic ventrobasal neurones. J. Physiol. 586, 965-987 (2008).
183. Porcello, D. M., Huntsman, M. M., Mihalek, R. M., Homanics, G. E. & Huguenard, J. R. Intact synaptic GABAergic inhibition and altered neurosteroid modulation of thalamic relay neurons in mice lacking delta subunit. J. Neurophysiol. 89, 1378-1386 (2003).
184. A receptors and increase tonic currents in thalamus. Neuropharmacology 56, 182-189 (2009).
185. A receptors in synapses of hippocampal pyramidal cells of the rat. Eur. J. Neurosci. 13, 428-442 (2001).
186. A receptors. Nature Rev. Neurosci. 6, 215-229 (2005).
187. A and glycine receptor-mediated transmission in rat lamina II neurones: relevance to the analgesic actions of neuroactive steroids. J. Physiol. 583, 1021-1040 (2007).
188. A receptor activity in rat hippocampus. J. Neurosci. 24, 6521-6530 (2004).
189. Ritchie, D. W. Evaluation of protein docking predictions using Hex 3.1 in CAPRI rounds 1 and 2. Proteins 52, 98-106 (2003).
190. Tsujishita, Y. & Hurley, J. H. Structure and lipid transport mechanism of a StAR-related domain. Nature Struct. Biol. 7, 408-414 (2000).
191. Arnold, K., Bordoli, L., Kopp, J. & Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006).
192. Schmidt, O. et al. Mode of action of antimicrobial proteins, pore-forming toxins and biologically active peptides (Hypothesis). Invertebrate Surv. J. 2, 82-90 (2005).
193. Wang, J., Sykes, B. D. & Ryan, R. O. Structural basis for the conformational adaptability of apolipophorin III, a helix-bundle exchangeable apolipoprotein. Proc. Natl Acad. Sci. USA 99, 1188-1193 (2002).
194. Cappelli, A. et al. Synthesis, labeling, and biological evaluation of halogenated 2-quinolinecarboxamides as potential radioligands for the visualization of peripheral benzodiazepine receptors. Bioorg. Med. Chem. 14, 4055-4066 (2006).
195. Primofiore, G. et al. N., N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor. J. Med. Chem. 47, 1852-1855 (2004).
196. Romeo, E. et al. 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J. Pharmacol. Exp. Ther. 262, 971-978 (1992).
197. Tarnok, K. et al. Effects of vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 53, 289-295 (2008).
198. 11 C[vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies. J. Neurol. Sci. 229-230, 219-223 (2005).
199. Taketani, S., Kohno, H., Furukawa, T. & Tokunaga, R. Involvement of peripheral-type benzodiazepine receptors in the intracellular transport of heme and porphyrins. J. Biochem. 11 7, 875-880 (1995).
200. Wendler, G., Lindemann, P., Lacapere, J. J. & Papadopoulos, V. Protoporphyrin IX binding and transport by recombinant mouse PBR. Biochem. Biophys. Res. Commun. 311, 847-852 (2003).
201. Penning, T. M., Jin, Y., Steckelbroeck, S., Lanisnik, R. T. & Lewis, M. Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. Mol. Cell. Endocrinol. 215, 63-72 (2004).
202. A receptor. Nature Rev. Neurosci. 6, 565-575 (2005).
203. A receptors through two discrete transmembrane sites. Nature 444, 486-489 (2006).
204. Park-Chung, M., Malayev, A., Purdy, R. H., Gibbs, T. T. & Farb, D. H. Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites. Brain Res. 830, 72-87 (1999).
205. A receptor channels from low- to high-efficacy gating patterns. J. Neurosci. 23, 10934-10943 (2003).
206. A receptor function by neuroactive steroids. Brain Res. 819, 75-82 (1999).
207. A receptors. Neuropharmacology 43, 651-661 (2002).